EMEA-003190-PIP01-22 - paediatric investigation plan

Botulinum toxin type E

Key facts

• Active Substance:
  Botulinum toxin type E
• Therapeutic area:
  Dermatology
• Decision number:
  P/0223/2022
• PIP number:
  EMEA-003190-PIP01-22
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of skin wrinkling
• Route(s) of administration:
  All routes of administration
• Contact for public enquiries:

  Allergan Pharmaceuticals Ireland

  [e-mail] ; [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  08/07/2022

Decision

P/0223/2022: EMA decision of 8 July 2022 on the granting of a product specific waiver for botulinum toxin type E (EMEA-003190-PIP01-22)

AdoptedReference Number: EMA/609038/2022